{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:46:14Z","timestamp":1791866774705,"version":"4.3.4"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01429-x","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:49:34Z","timestamp":1787989774000},"page":"2977-3002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Live Attenuated Influenza Vaccine (LAIV) for Children for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Petter","family":"Brodin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fryderyk","family":"Wilczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Ricci Pacifici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6002-7105","authenticated-orcid":false,"given":"Peter D.","family":"Gabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Prudden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Magnatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hallberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Tuovinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Tormod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klas","family":"Bergenheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"1429_CR1","unstructured":"World Health Organization. Influenza (Seasonal). 2025. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal) Accessed 8 Apr 2026."},{"key":"1429_CR2","unstructured":"Folkh\u00e4lsomyndigheten. Influenza in Sweden\u2014Season 2024-2025. 2025. Available at: https:\/\/www.folkhalsomyndigheten.se\/publikationer-och-material\/publikationsarkiv\/i\/influenza-in-sweden-season-2024-2025\/?pub=147447 Accessed 17 Nov 2025."},{"key":"1429_CR3","doi-asserted-by":"publisher","first-page":"100666","DOI":"10.1016\/j.jvacx.2025.100666","volume":"25","author":"A Bandell","year":"2019","unstructured":"Bandell A, Kassianos G, Dibben O, et\u00a0al. Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019\u20132023). Vaccine X. 2019;25:100666.","journal-title":"Vaccine X"},{"key":"1429_CR4","doi-asserted-by":"publisher","first-page":"101124","DOI":"10.1016\/j.arr.2020.101124","volume":"62","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Cao X, Cao Z, et\u00a0al. Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality. Ageing Res Rev. 2020;62:101124.","journal-title":"Ageing Res Rev"},{"issue":"42","key":"1429_CR5","doi-asserted-by":"publisher","first-page":"30378","DOI":"10.2807\/1560-7917.ES.2016.21.42.30378","volume":"21","author":"D Mertz","year":"2016","unstructured":"Mertz D, Fadel SA, Lam PP, et\u00a0al. Herd effect from influenza vaccination in non-healthcare settings: a systematic review of randomised controlled trials and observational studies. Euro Surveill. 2016;21(42):30378.","journal-title":"Euro Surveill"},{"issue":"13","key":"1429_CR6","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.vaccine.2004.09.025","volume":"23","author":"PA Piedra","year":"2005","unstructured":"Piedra PA, Gaglani MJ, Kozinetz CA, et\u00a0al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005;23(13):1540\u20138.","journal-title":"Vaccine"},{"issue":"1","key":"1429_CR7","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1186\/s12889-024-18694-5","volume":"24","author":"TR de Fougerolles","year":"2024","unstructured":"de Fougerolles TR, Ba\u00efssas T, Perquier G, et\u00a0al. Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives. BMC Public Health. 2024;24(1):1222.","journal-title":"BMC Public Health"},{"issue":"5","key":"1429_CR8","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/irv.12991","volume":"16","author":"L Villani","year":"2022","unstructured":"Villani L, D\u2019Ambrosio F, Ricciardi R, et\u00a0al. Seasonal influenza in children: costs for the health system and society in Europe. Influenza Other Respir Viruses. 2022;16(5):820\u201331.","journal-title":"Influenza Other Respir Viruses"},{"issue":"23","key":"1429_CR9","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1016\/j.vaccine.2006.03.057","volume":"24","author":"H Salo","year":"2006","unstructured":"Salo H, Kilpi T, Sintonen H, et\u00a0al. Cost-effectiveness of influenza vaccination of healthy children. Vaccine. 2006;24(23):4934\u201341.","journal-title":"Vaccine"},{"issue":"9","key":"1429_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00431-025-06450-9","volume":"184","author":"G Brisca","year":"2025","unstructured":"Brisca G, Mariani M, Bellini T, et\u00a0al. Increase in benign acute childhood myositis in the post-COVID era: a retrospective study from a tertiary pediatric center. Eur J Pediatr. 2025;184(9):599.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"1429_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1046\/j.1442-200x.2000.01202.x","volume":"42","author":"T Togashi","year":"2000","unstructured":"Togashi T, Matsuzono Y, Narita M. Epidemiology of influenza-associated encephalitis-encephalopathy in Hokkaido, the northernmost island of Japan. Pediatr Int. 2000;42(2):192\u20136.","journal-title":"Pediatr Int"},{"issue":"11","key":"1429_CR12","doi-asserted-by":"publisher","first-page":"e2446814","DOI":"10.1001\/jamanetworkopen.2024.46814","volume":"7","author":"CG Grijalva","year":"2024","unstructured":"Grijalva CG, Nguyen HQ, Zhu Y, et\u00a0al. Estimated effectiveness of influenza vaccines in preventing secondary infections in households. JAMA Netw Open. 2024;7(11):e2446814.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1429_CR13","doi-asserted-by":"publisher","first-page":"e1012454","DOI":"10.1371\/journal.pcbi.1012454","volume":"20","author":"K Prem","year":"2024","unstructured":"Prem K, Zandvoort K, Klepac P, et\u00a0al. Correction: projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the COVID-19 era. PLoS Comput Biol. 2024;20(9):e1012454.","journal-title":"PLoS Comput Biol"},{"issue":"9","key":"1429_CR14","doi-asserted-by":"publisher","first-page":"pgae338","DOI":"10.1093\/pnasnexus\/pgae338","volume":"3","author":"SE Morris","year":"2024","unstructured":"Morris SE, Nguyen HQ, Grijalva CG, et\u00a0al. Influenza virus shedding and symptoms: dynamics and implications from a multiseason household transmission study. PNAS Nexus. 2024;3(9):pgae338.","journal-title":"PNAS Nexus."},{"key":"1429_CR15","unstructured":"Folkh\u00e4lsomyndigheten. Vaccination programmes and recommendations. 2022. Available at: https:\/\/www.folkhalsomyndigheten.se\/the-public-health-agency-of-sweden\/communicable-disease-control\/vaccinations\/vaccination-programmes\/ Accessed 8 Feb 2024."},{"issue":"9","key":"1429_CR16","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.3390\/vaccines10091466","volume":"10","author":"KS-K Chan","year":"2022","unstructured":"Chan KS-K, Wong CH-L, Choi HC-W. Cost-effectiveness of intranasal live-attenuated influenza vaccine for children: a systematic review. Vaccines (Basel). 2022;10(9):1466.","journal-title":"Vaccines (Basel)"},{"key":"1429_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091388","author":"ER De Gioia","year":"2022","unstructured":"De Gioia ER, Porqueddu A, Nebiaj O, et\u00a0al. The role of needle fear in pediatric flu vaccine hesitancy: a cross-sectional study in Bologna metropolitan area. Vaccines (Basel). 2022. https:\/\/doi.org\/10.3390\/vaccines10091388.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"1429_CR18","doi-asserted-by":"publisher","first-page":"2328406","DOI":"10.1080\/21645515.2024.2328406","volume":"20","author":"M Zornoza Moreno","year":"2024","unstructured":"Zornoza Moreno M, P\u00e9rez-Mart\u00edn J, Robles Ma\u00f1ueco M. Parents and teachers\u2019 perspectives on a school-located influenza vaccination program: a pilot study in the region of Murcia, Spain. Hum Vaccin Immunother. 2024;20(1):2328406.","journal-title":"Hum Vaccin Immunother"},{"key":"1429_CR19","doi-asserted-by":"publisher","first-page":"126675","DOI":"10.1016\/j.vaccine.2024.126675","volume":"46","author":"HC Maltezou","year":"2025","unstructured":"Maltezou HC, Poland GA, de Lejarazu RO. Influenza vaccination for children in Europe: the health of every child matters. Vaccine. 2025;46:126675.","journal-title":"Vaccine"},{"issue":"2","key":"1429_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/infdis\/jiae434","volume":"231","author":"C Zhang","year":"2024","unstructured":"Zhang C, Fang VJ, Chan K-H, et\u00a0al. Interplay between viral shedding, age, and symptoms in individual infectiousness of influenza cases in households. J Infect Dis. 2024;231(2):462\u201370.","journal-title":"J Infect Dis"},{"issue":"6","key":"1429_CR21","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.vaccine.2011.11.106","volume":"30","author":"R Pitman","year":"2012","unstructured":"Pitman R, White L, Sculpher M. Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. Vaccine. 2012;30(6):1208\u201324.","journal-title":"Vaccine"},{"issue":"159","key":"1429_CR22","doi-asserted-by":"publisher","first-page":"200258","DOI":"10.1183\/16000617.0258-2020","volume":"30","author":"AR Tanner","year":"2021","unstructured":"Tanner AR, Dorey RB, Brendish NJ, et\u00a0al. Influenza vaccination: protecting the most vulnerable. Eur Respir Rev. 2021;30(159):200258.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"1429_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jval.2020.10.011","volume":"24","author":"PT de Boer","year":"2021","unstructured":"de Boer PT, Nagy L, Dolk FC, et\u00a0al. Cost-effectiveness of pediatric influenza vaccination in the Netherlands. Value Health. 2021;24(1):19\u201331.","journal-title":"Value Health"},{"issue":"9","key":"1429_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s40273-016-0430-z","volume":"34","author":"L Nagy","year":"2016","unstructured":"Nagy L, Heikkinen T, Sackeyfio A, et\u00a0al. The clinical impact and cost effectiveness of quadrivalent versus trivalent influenza vaccination in Finland. Pharmacoeconomics. 2016;34(9):939\u201351.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1429_CR25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.vaccine.2012.12.010","volume":"31","author":"RJ Pitman","year":"2013","unstructured":"Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales: results from a dynamic transmission model. Vaccine. 2013;31(6):927\u201342.","journal-title":"Vaccine"},{"issue":"1","key":"1429_CR26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12916-017-0932-3","volume":"15","author":"D Thorrington","year":"2017","unstructured":"Thorrington D, van Leeuwen E, Ramsay M, et\u00a0al. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England. BMC Med. 2017;15(1):166.","journal-title":"BMC Med"},{"key":"1429_CR27","unstructured":"Statistiska Centralbyr\u00e5n SCB. Mean population (by year of birth) by region, age and sex. Year 2025. 2026. Available at: https:\/\/www.statistikdatabasen.scb.se\/pxweb\/en\/ssd\/START__BE__BE0101__BE0101D\/MedelfolkFodarCKM\/table\/tableViewLayout1\/ Accessed 3 Mar 2026."},{"key":"1429_CR28","unstructured":"Folkh\u00e4lsomyndigheten. Influenza in Sweden\u2014Season 2014-2015. 2015 Available at: https:\/\/www.folkhalsomyndigheten.se\/contentassets\/e33657cab0bf4d99be98a976ec423c9f\/influenza-in-sweden-2014-2015.pdf Accessed 16 Aug 2024."},{"key":"1429_CR29","unstructured":"Folkh\u00e4lsomyndigheten. Influenza in Sweden\u2014Season 2015-2016. 2016 Available at: https:\/\/www.icuregswe.org\/globalassets\/dokument\/influenza-in-sweden-2015-2016.pdf Accessed 20 Jan 2024."},{"key":"1429_CR30","unstructured":"Folkh\u00e4lsomyndigheten. Influenza in Sweden\u2014Season 2016-2017. 2017. Available at: https:\/\/www.icuregswe.org\/globalassets\/dokument\/influenza-in-sweden-2016-2017.pdf Accessed 20 Jan 2024."},{"key":"1429_CR31","unstructured":"Folkh\u00e4lsomyndigheten. Influenza in Sweden\u2014Season 2017-2018. 2018. Available at: https:\/\/www.icuregswe.org\/globalassets\/dokument\/influenza-in-sweden-2017_2018.pdf Accessed 20 Jan 2024."},{"key":"1429_CR32","unstructured":"Folkh\u00e4lsomyndigheten. Influenza in Sweden\u2014Season 2018-2019. 2019. Available at: https:\/\/www.icuregswe.org\/globalassets\/dokument\/influenza-in-sweden---season-2018_2019.pdf Accessed 20 Jan 2024."},{"key":"1429_CR33","unstructured":"Folkh\u00e4lsomyndigheten. Influenza in Sweden\u2014Season 2019-2020. 2020. Available at: https:\/\/www.folkhalsomyndigheten.se\/publikationer-och-material\/publikationsarkiv\/i\/influenza-in-sweden-2019-2020-season\/ Accessed 20 Jan 2024."},{"issue":"3","key":"1429_CR34","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1371\/journal.pmed.0050074","volume":"5","author":"J Mossong","year":"2008","unstructured":"Mossong J, Hens N, Jit M, et\u00a0al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):e74.","journal-title":"PLoS Med"},{"issue":"12","key":"1429_CR35","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s40273-016-0443-7","volume":"34","author":"C Dolk","year":"2016","unstructured":"Dolk C, Eichner M, Welte R, et\u00a0al. Cost-utility of quadrivalent versus trivalent influenza vaccine in Germany, using an individual-based dynamic transmission model. Pharmacoeconomics. 2016;34(12):1299\u2013308.","journal-title":"Pharmacoeconomics"},{"issue":"41","key":"1429_CR36","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1016\/j.vaccine.2023.08.031","volume":"41","author":"NR Waterlow","year":"2023","unstructured":"Waterlow NR, Procter SR, van Leeuwen E, et\u00a0al. The potential cost-effectiveness of next generation influenza vaccines in England and Wales: a modelling analysis. Vaccine. 2023;41(41):6017\u201324.","journal-title":"Vaccine"},{"key":"1429_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00619-9","author":"MP Montgomery","year":"2023","unstructured":"Montgomery MP, Morris SE, Rolfes MA, et\u00a0al. The role of asymptomatic infections in influenza transmission: what do we really know. Lancet Infect Dis. 2023. https:\/\/doi.org\/10.1016\/S1473-3099(23)00619-9.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"1429_CR38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/aje\/kwm375","volume":"167","author":"F Carrat","year":"2008","unstructured":"Carrat F, Vergu E, Ferguson NM, et\u00a0al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167(7):775\u201385.","journal-title":"Am J Epidemiol"},{"issue":"33","key":"1429_CR39","doi-asserted-by":"publisher","first-page":"e2304750120","DOI":"10.1073\/pnas.2304750120","volume":"120","author":"TK Tsang","year":"2023","unstructured":"Tsang TK, Wang C, Fang VJ, et\u00a0al. Reconstructing household transmission dynamics to estimate the infectiousness of asymptomatic influenza virus infections. Proc Natl Acad Sci U S A. 2023;120(33):e2304750120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1429_CR40","unstructured":"World Health Organization. Influenza laboratory surveillance information. 2024."},{"key":"1429_CR41","unstructured":"National Board of Health and Welfare (Socialstyrelsen). Statistical database report (data on file). Diagnoses, hospitalisations (cases) due to influenza, all Sweden, male and female 2025."},{"issue":"1","key":"1429_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13052-024-01649-2","volume":"50","author":"S Roncaglia","year":"2022","unstructured":"Roncaglia S, Amendola A, Baldassarre P, et\u00a0al. Quadrivalent live-attenuated influenza vaccine in Milan preschools: an Italian experience of school-located flu vaccination within the 2022\u20132023 season. Ital J Pediatr. 2022;50(1):97.","journal-title":"Ital J Pediatr"},{"key":"1429_CR43","unstructured":"Terveyden ja hyvinvoinnin laitos (THL). Map: Influenza vaccination coverage. Available at: https:\/\/www.thl.fi\/roko\/vaccreg\/atlas\/public\/atlas-en.html?show=influenza Accessed 30 Oct 2024."},{"key":"1429_CR44","unstructured":"UK Health Security Agency. Seasonal influenza vaccine uptake in children of school age in England: winter season 2024 to 2025. 2025. Available at: https:\/\/www.gov.uk\/government\/statistics\/seasonal-influenza-vaccine-uptake-in-children-of-school-age-winter-season-2024-to-2025\/seasonal-influenza-vaccine-uptake-in-children-of-school-age-in-england-winter-season-2024-to-2025 Accessed 30 Oct 2025."},{"issue":"1","key":"1429_CR45","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/14760584.2025.2536087","volume":"24","author":"AL Stuurman","year":"2003","unstructured":"Stuurman AL, Enxing J, Guti\u00e9rrez AV, et\u00a0al. Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis. Expert Rev Vaccines. 2003;24(1):703\u201325.","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"1429_CR46","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3390\/vaccines11091450","volume":"11","author":"M Fornaguera","year":"2021","unstructured":"Fornaguera M, Par\u00e9s-Badell O, Carbon\u00e9s-Fargas \u00cd, et\u00a0al. Influenza vaccine effectiveness against hospitalization, season 2021\/22: a test-negative design study in Barcelona. Vaccines (Basel). 2021;11(9):1450.","journal-title":"Vaccines (Basel)"},{"key":"1429_CR47","unstructured":"Askar M, Batke M, Brugger T, et\u00a0al. Systematic review update on the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over. Eur Centre Dis Prevent Control. 2024."},{"key":"1429_CR48","unstructured":"El Azzi G, Gangadharaiah S, Druelles S, et\u00a0al. 20 Years of use: long-term safety profile of live attenuated influenza vaccine. 9th Influenza Conference 2023; Valencia: European Scientific Working Group on Influenza; 2023."},{"issue":"7","key":"1429_CR49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1023\/A:1013171831202","volume":"10","author":"K Burstr\u00f6m","year":"2001","unstructured":"Burstr\u00f6m K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10(7):621\u201335.","journal-title":"Qual Life Res"},{"issue":"2","key":"1429_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen MF, Szende A, Cabases J, et\u00a0al. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205\u201316.","journal-title":"Eur J Health Econ"},{"key":"1429_CR51","unstructured":"Statistiska Centralbyr\u00e5n SCB. Life table by sex and age. Year 1960 - 2025. 2026. Available at: https:\/\/www.statistikdatabasen.scb.se\/pxweb\/en\/ssd\/START__BE__BE0101__BE0101I\/LivslangdEttariga\/ Accessed 3 Mar 2026."},{"key":"1429_CR52","unstructured":"Apoteket Hj\u00e4rtat. Vaxigrip Injektionsv\u00e4tska, suspension, f\u00f6rfylld spruta F\u00f6rfylld spruta, 10st, utan n\u00e5l. 2026. Available at: https:\/\/www.apotekhjartat.se\/rx\/manniska\/rx-j\/vaxigrip-injektionsvatska-suspension-forfylld-spruta-forfylld-spruta-10st-utan-nal Accessed 2 Mar 2026."},{"key":"1429_CR53","unstructured":"Apoteket Hj\u00e4rtat. Fluarix Injektionsv\u00e4tska, suspension, f\u00f6rfylld spruta F\u00f6rfylld spruta, 10st (utan n\u00e5l). 2026. Available at: https:\/\/www.apotekhjartat.se\/rx\/manniska\/rx-j\/fluarix-injektionsvatska-suspension-forfylld-spruta-forfylld-spruta-10st-utan-nal Accessed 2 Mar 2026."},{"key":"1429_CR54","unstructured":"Kronans Apotek. Fluenz. Vaccin mot influensa, levande f\u00f6rsvagat, N\u00e4sspray, suspension, 10 x 0.2 milliliter. 2026. Available at: https:\/\/www.kronansapotek.se\/Fluenz\/p\/129960\/ Accessed 2 Mar 2026."},{"key":"1429_CR55","unstructured":"Region S\u00f6rmland. Prislista till regelbok f\u00f6r v\u00e5rdval v\u00e5rdcentral i Region S\u00f6rmland. Kvalitets- och h\u00e4lsoers\u00e4ttning. TBE-vaccination av barn fr\u00e5n dagen man fyller 3 \u00e5r till och med dagen man fyller 20 \u00e5r. 2025. Available at: https:\/\/samverkan.regionsormland.se\/for-vardgivare\/vardval-primarvard-halsoval\/regelbok-for-vardval-vardcentral\/ Accessed 2 Mar 2026."},{"key":"1429_CR56","unstructured":"S\u00f6dra sjukv\u00e5rdsregionen. Regionala priser och ers\u00e4ttningar. 4.2 \u00d6vrig offentlig v\u00e5rd. L\u00e4karbes\u00f6k (inklusive all medicinsk service). 2025. Available at: https:\/\/sodrasjukvardsregionen.se\/verksamhet\/avtal-priser\/ Accessed 2 Mar 2026."},{"key":"1429_CR57","unstructured":"S\u00f6dra sjukv\u00e5rdsregionen. Regionala priser och ers\u00e4ttningar. Bilaga 3, kap 2.1.1.3 Prislista Sk\u00e5nes universitetssjukhus. Verksamhetsomr\u00e5de infektionssjukdomar. Varddag Omv\u00e5rdnadsdag. 2025. Available at: https:\/\/sodrasjukvardsregionen.se\/verksamhet\/avtal-priser\/ Accessed 2 Mar 2026."},{"key":"1429_CR58","unstructured":"S\u00f6dra sjukv\u00e5rdsregionen. Regionala priser och ers\u00e4ttningar. 2.1.1.2 V\u00e5rdtj\u00e4nster per klinik. Verksamhetsomr\u00e5de intensiv- och perioperativ v\u00e5rd. Intensiv och perioperativ v\u00e5rd. VARDDAGCIVA. Omv\u00e5rdnadsdag, COVID. 2023. Available at: https:\/\/sodrasjukvardsregionen.se\/download\/regionala-priser-och-ersattningar-for-sodra-sjukvardsregionen-2023\/ Accessed 13 Aug 2024."},{"key":"1429_CR59","unstructured":"Statistiska Centralbyr\u00e5n SCB. Population aged 15-74 (LFS) by labour status, type of data, sex and age. Year 2001\u20132025. 2026. Available at: https:\/\/www.statistikdatabasen.scb.se\/pxweb\/en\/ssd\/START__AM__AM0401__AM0401A\/AKURLBefAr\/ Accessed 3 Mar 2026."},{"key":"1429_CR60","unstructured":"Statistiska Centralbyr\u00e5n SCB. Average basic salary, monthly salary and women\u00b4s salary as a percentage of men\u2019s salary by sector, occupation (SSYK 2012) , sex and age. Year 2023\u20132024. 2026. Available at: https:\/\/www.statistikdatabasen.scb.se\/pxweb\/en\/ssd\/START__AM__AM0110__AM0110A\/LonYrkeAlder4AN\/ Accessed 3 Mar 2026."},{"issue":"1","key":"1429_CR61","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jval.2025.07.027","volume":"29","author":"APH Klockhoff","year":"2026","unstructured":"Klockhoff APH, Siverskog J, Henriksson M. Pharmaceutical pricing evidence from a healthcare system with multiple cost-per-quality-adjusted life-year thresholds. Value Health. 2026;29(1):92\u20139.","journal-title":"Value Health"},{"key":"1429_CR62","unstructured":"Persson U. Value based pricing in Sweden: lessons for design. 2012. Available at: https:\/\/www.ohe.org\/wp-content\/uploads\/2014\/07\/377-VBP-in-Sweden-Persson-2012.pdf Accessed 17 Oct 2025."},{"issue":"12","key":"1429_CR63","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1016\/j.jval.2022.09.1686","volume":"25","author":"J Viollet","year":"2014","unstructured":"Viollet J, O\u2019Leary E, Camacho Gonzalez C, et\u00a0al. HTA228 willingness to pay for different severity levels in Sweden: an analysis of TLV decisions (2014-2022). Value Health. 2014;25(12):S341.","journal-title":"Value Health"},{"key":"1429_CR64","unstructured":"Sveriges Riksbank. Search interest rates and exchange rates. 2025. Available at: https:\/\/www.riksbank.se\/en-gb\/statistics\/interest-rates-and-exchange-rates\/search-annual-and-monthly-average-exchange-rates\/ Accessed 12 Jun 2026."},{"issue":"1","key":"1429_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et\u00a0al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10\u201331.","journal-title":"Value Health"},{"key":"1429_CR66","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10198-014-0586-4","volume":"16","author":"O Damm","year":"2015","unstructured":"Damm O, Eichner M, Rose MA, et\u00a0al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ. 2015;16:471\u201388.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1429_CR67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2334-14-40","volume":"14","author":"MA Rose","year":"2014","unstructured":"Rose MA, Damm O, Greiner W, et\u00a0al. The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infect Dis. 2014;14(1):40.","journal-title":"BMC Infect Dis"},{"key":"1429_CR68","doi-asserted-by":"publisher","first-page":"128478","DOI":"10.1016\/j.vaccine.2026.128478","volume":"79","author":"Q Ye","year":"2023","unstructured":"Ye Q, Chen H, Jia B, et\u00a0al. Uptake and effectiveness of a novel seasonal influenza vaccination campaign for school-age children in the 2023\/2024 influenza season in Shanghai, China. Vaccine. 2023;79:128478.","journal-title":"Vaccine"},{"issue":"5","key":"1429_CR69","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/14737167.2021.1925110","volume":"21","author":"S Boccalini","year":"2021","unstructured":"Boccalini S, Bechini A, Moscadelli A, et\u00a0al. Cost-effectiveness of childhood influenza vaccination in Europe: results from a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):911\u201322.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5761","key":"1429_CR70","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1126\/science.1122143","volume":"311","author":"ME Halloran","year":"2006","unstructured":"Halloran ME, Longini IM. Community studies for vaccinating schoolchildren against influenza. Science. 2006;311(5761):615\u20136.","journal-title":"Science"},{"issue":"1","key":"1429_CR71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12889-021-12426-9","volume":"22","author":"F Trentini","year":"2022","unstructured":"Trentini F, Pariani E, Bella A, et\u00a0al. Characterizing the transmission patterns of seasonal influenza in Italy: lessons from the last decade. BMC Public Health. 2022;22(1):19.","journal-title":"BMC Public Health"},{"key":"1429_CR72","doi-asserted-by":"publisher","first-page":"104970","DOI":"10.1016\/j.antiviral.2020.104970","volume":"185","author":"H Zaraket","year":"2021","unstructured":"Zaraket H, Hurt AC, Clinch B, et\u00a0al. Burden of influenza B virus infection and considerations for clinical management. Antivir Res. 2021;185:104970.","journal-title":"Antivir Res"},{"issue":"9","key":"1429_CR73","doi-asserted-by":"publisher","first-page":"e1005697","DOI":"10.1371\/journal.pcbi.1005697","volume":"13","author":"K Prem","year":"2017","unstructured":"Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput Biol. 2017;13(9):e1005697.","journal-title":"PLoS Comput Biol"},{"key":"1429_CR74","doi-asserted-by":"publisher","first-page":"127467","DOI":"10.1016\/j.vaccine.2025.127467","volume":"62","author":"J Gilroy","year":"2025","unstructured":"Gilroy J, O\u2019Leary M, Domegan L, et\u00a0al. Increasing the uptake of live attenuated influenza vaccine through a new school-based vaccination programme in Ireland. Vaccine. 2025;62:127467.","journal-title":"Vaccine"},{"key":"1429_CR75","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.epidem.2025.100826","volume":"51","author":"R Manansala","year":"2025","unstructured":"Manansala R, Bilcke J, Willem L, et\u00a0al. Optimizing influenza vaccine allocation by age using cost-effectiveness analysis: a comparison of 6720 vaccination program scenarios in children and adults in Belgium. Epidemics. 2025;51:100826.","journal-title":"Epidemics"},{"issue":"1","key":"1429_CR76","doi-asserted-by":"publisher","first-page":"2497207","DOI":"10.1080\/21645515.2025.2497207","volume":"21","author":"J P\u00e9rez-Mart\u00edn","year":"2025","unstructured":"P\u00e9rez-Mart\u00edn J, Zornoza Moreno M, Bernal-Alonso A. Influenza school-based vaccination: a way to increase equity among children. Hum Vaccin Immunother. 2025;21(1):2497207.","journal-title":"Hum Vaccin Immunother"},{"key":"1429_CR77","doi-asserted-by":"publisher","first-page":"212280","DOI":"10.7573\/dic.212280","volume":"4","author":"G Kassianos","year":"2015","unstructured":"Kassianos G, White S, Reynolds AJ, et\u00a0al. Review of the experiences from the first childhood influenza vaccination programme with a live attenuated influenza vaccine in England and Scotland. Drugs Context. 2015;4:212280.","journal-title":"Drugs Context."},{"issue":"39","key":"1429_CR78","first-page":"30029","volume":"20","author":"RG Pebody","year":"2014","unstructured":"Pebody RG, Green HK, Andrews N, et\u00a0al. Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014\/15. Euro Surveill. 2014;20(39):30029.","journal-title":"Euro Surveill"},{"issue":"6","key":"1429_CR79","doi-asserted-by":"publisher","first-page":"e70131","DOI":"10.1111\/irv.70131","volume":"19","author":"U Baum","year":"2025","unstructured":"Baum U, Ikonen N, Luomala O, et\u00a0al. Influenza epidemiology in Finland during and after the COVID-19 pandemic: surveillance data analysis (2019\u20132024). Influenza Other Respir Viruses. 2025;19(6):e70131.","journal-title":"Influenza Other Respir Viruses"},{"issue":"5","key":"1429_CR80","doi-asserted-by":"publisher","first-page":"e0316131","DOI":"10.1371\/journal.pone.0316131","volume":"20","author":"S Foulkes","year":"2022","unstructured":"Foulkes S, Munro K, Sparkes D, et\u00a0al. Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022\/23: results of a pilot study in the SIREN cohort. PLoS ONE. 2022;20(5):e0316131.","journal-title":"PLoS ONE"},{"issue":"1","key":"1429_CR81","doi-asserted-by":"publisher","first-page":"2521912","DOI":"10.1080\/21645515.2025.2521912","volume":"21","author":"AC Langedijk","year":"2025","unstructured":"Langedijk AC, van den Dungen F, Harteveld L, et\u00a0al. Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands. Hum Vaccin Immunother. 2025;21(1):2521912.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"1429_CR82","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40273-020-00991-7","volume":"39","author":"M Treskova","year":"2021","unstructured":"Treskova M, Pozo-Martin F, Scholz S, et\u00a0al. Assessment of the effects of active immunisation against respiratory syncytial virus (RSV) using decision-analytic models: a systematic review with a focus on vaccination strategies, modelling methods and input data. Pharmacoeconomics. 2021;39(3):287\u2013315.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1429_CR83","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.cmi.2019.06.030","volume":"25","author":"BS Buckley","year":"2019","unstructured":"Buckley BS, Henschke N, Bergman H, et\u00a0al. Impact of vaccination on antibiotic usage: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(10):1213\u201325.","journal-title":"Clin Microbiol Infect"},{"issue":"23","key":"1429_CR84","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1016\/S0264-410X(03)00253-6","volume":"21","author":"S Esposito","year":"2003","unstructured":"Esposito S, Marchisio P, Cavagna R, et\u00a0al. Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine. 2003;21(23):3162\u20138.","journal-title":"Vaccine"},{"issue":"10","key":"1429_CR85","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/INF.0b013e3181a487b4","volume":"28","author":"P Marchisio","year":"2009","unstructured":"Marchisio P, Esposito S, Bianchini S, et\u00a0al. Efficacy of injectable trivalent virosomal-adjuvanted inactivated influenza vaccine in preventing acute otitis media in children with recurrent complicated or noncomplicated acute otitis media. Pediatr Infect Dis J. 2009;28(10):855\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"10 Suppl","key":"1429_CR86","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1097\/01.inf.0000092188.48726.e4","volume":"22","author":"N Principi","year":"2003","unstructured":"Principi N, Esposito S, Marchisio P, et\u00a0al. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J. 2003;22(10 Suppl):S207\u201310.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"1429_CR87","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13756-023-01272-6","volume":"12","author":"L van Heuvel","year":"2023","unstructured":"van Heuvel L, Paget J, D\u00fcckers M, et\u00a0al. The impact of influenza and pneumococcal vaccination on antibiotic use: an updated systematic review and meta-analysis. Antimicrob Resist Infect Control. 2023;12(1):70.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"12","key":"1429_CR88","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram MY, Lauer JA, De Joncheere K, et\u00a0al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925\u201330.","journal-title":"Bull World Health Organ"},{"issue":"3","key":"1429_CR89","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1017\/S095026880200780X","volume":"129","author":"B Christenson","year":"2002","unstructured":"Christenson B, Lundbergh P. Comparison between cohorts vaccinated and unvaccinated against influenza and pneumococcal infection. Epidemiol Infect. 2002;129(3):515\u201324.","journal-title":"Epidemiol Infect"},{"issue":"8","key":"1429_CR90","doi-asserted-by":"publisher","first-page":"e0134928","DOI":"10.1371\/journal.pone.0134928","volume":"10","author":"RD Pockett","year":"2015","unstructured":"Pockett RD, Watkins J, McEwan P, et\u00a0al. Burden of illness in UK subjects with reported respiratory infections vaccinated or unvaccinated against influenza: a retrospective observational study. PLoS ONE. 2015;10(8):e0134928.","journal-title":"PLoS ONE"},{"issue":"5","key":"1429_CR91","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, et\u00a0al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force\u20137. Med Decis Making. 2012;32(5):733\u201343.","journal-title":"Med Decis Making"},{"issue":"21","key":"1429_CR92","first-page":"2500743","volume":"31","author":"M Del Riccio","year":"2020","unstructured":"Del Riccio M, Caini S. Global influenza epidemiology after 2020: patterns of circulation, epidemic timing and duration, and implications for vaccination strategies. Euro Surveill. 2020;31(21):2500743.","journal-title":"Euro Surveill"},{"issue":"6","key":"1429_CR93","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/EDE.0000000000000340","volume":"26","author":"NH Leung","year":"2015","unstructured":"Leung NH, Xu C, Ip DK, et\u00a0al. Review article: the fraction of influenza virus infections that are asymptomatic: a systematic review and meta-analysis. Epidemiology. 2015;26(6):862\u201372.","journal-title":"Epidemiology"},{"key":"1429_CR94","unstructured":"UK Health Security Agency. Influenza: the green book, chapter 19. 2025. Available at: https:\/\/www.gov.uk\/government\/publications\/influenza-the-green-book-chapter-19 Accessed 16 Jun 2025."},{"issue":"2","key":"1429_CR95","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.vaccine.2020.10.007","volume":"39","author":"NS Wenzel","year":"2021","unstructured":"Wenzel NS, Atkins KE, Van Leeuwen E, et\u00a0al. Cost-effectiveness of live-attenuated influenza vaccination among school-age children. Vaccine. 2021;39(2):447\u201356.","journal-title":"Vaccine"},{"issue":"3","key":"1429_CR96","doi-asserted-by":"publisher","first-page":"106443","DOI":"10.1016\/j.jinf.2025.106443","volume":"90","author":"KV Williams","year":"2025","unstructured":"Williams KV, Krauland MG, Nowalk MP, et\u00a0al. Increasing child vaccination coverage can reduce influenza cases across age groups: an agent-based modeling study. J Infect. 2025;90(3):106443.","journal-title":"J Infect"},{"key":"1429_CR97","unstructured":"Statistiska Centralbyr\u00e5n SCB. Crude birth rate. The ratio of the number of live births to the average population by region. Year 2010\u20132025. 2026. Available at: https:\/\/www.statistikdatabasen.scb.se\/pxweb\/en\/ssd\/START__BE__BE0101__BE0101H\/FodelstalHVD\/ Accessed 3 Mar 2026."},{"issue":"7","key":"1429_CR98","doi-asserted-by":"publisher","first-page":"e1009098","DOI":"10.1371\/journal.pcbi.1009098","volume":"17","author":"K Prem","year":"2021","unstructured":"Prem K, Zandvoort K, Klepac P, et\u00a0al. Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the COVID-19 era. PLoS Comput Biol. 2021;17(7):e1009098.","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"1429_CR99","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.1016\/S2214-109X(21)00141-8","volume":"9","author":"C Cohen","year":"2017","unstructured":"Cohen C, Kleynhans J, Moyes J, et\u00a0al. Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017-18 (PHIRST): a population cohort study. Lancet Glob Health. 2017;9(6):e863\u201374.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"1429_CR100","doi-asserted-by":"publisher","first-page":"e1007096","DOI":"10.1371\/journal.pcbi.1007096","volume":"15","author":"EM Hill","year":"2019","unstructured":"Hill EM, Petrou S, de Lusignan S, et\u00a0al. Seasonal influenza: modelling approaches to capture immunity propagation. PLoS Comput Biol. 2019;15(10):e1007096.","journal-title":"PLoS Comput Biol"},{"issue":"10","key":"1429_CR101","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1046\/j.1525-1497.2003.20822.x","volume":"18","author":"MB Rothberg","year":"2003","unstructured":"Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults. J Gen Intern Med. 2003;18(10):808\u201315.","journal-title":"J Gen Intern Med"},{"issue":"11","key":"1429_CR102","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s100960000376","volume":"19","author":"CR Meier","year":"2000","unstructured":"Meier CR, Napalkov PN, Wegm\u00fcller Y, et\u00a0al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis. 2000;19(11):834\u201342.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"1429_CR103","doi-asserted-by":"publisher","first-page":"e102634","DOI":"10.1371\/journal.pone.0102634","volume":"9","author":"J Bilcke","year":"2014","unstructured":"Bilcke J, Coenen S, Beutels P. Influenza-like-illness and clinically diagnosed flu: disease burden, costs and quality of life for patients seeking ambulatory care or no professional care at all. PLoS ONE. 2014;9(7):e102634.","journal-title":"PLoS ONE"},{"issue":"1","key":"1429_CR104","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1080\/13696998.2021.1908000","volume":"24","author":"R Cai","year":"2021","unstructured":"Cai R, Gerlier L, Eichner M, et\u00a0al. Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany. J Med Econ. 2021;24(1):490\u2013501.","journal-title":"J Med Econ"},{"issue":"2","key":"1429_CR105","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/archpediatrics.2010.182","volume":"165","author":"LA Prosser","year":"2011","unstructured":"Prosser LA, Meltzer MI, Fiore A, et\u00a0al. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. Arch Pediatr Adolesc Med. 2011;165(2):112\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"1429_CR106","unstructured":"Apoteket. Otrivin, n\u00e4sspray, l\u00f6sning 1 mg\/ml, 10 ml. 2026. Available at: https:\/\/www.apoteket.se\/produkt\/otrivin-nasspray-losning-1-mg-per-ml-10-ml-flaska-57103\/ Accessed 2 Mar 2026."},{"key":"1429_CR107","unstructured":"Tandv\u00e5rdsoch-L\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). Periodens varor. Mars 2026. Fenoximetylpenicillin, 1g, 30 tbl. Varunummer 087094. 2026. Available at: https:\/\/www.tlv.se\/webdav\/files\/Periodens-vara\/periodens-vara-mars-20260301.xlsx Accessed 3 Mar 2026."},{"key":"1429_CR108","unstructured":"Adda Ink\u00f6pscentral AB. Influensavaccin s\u00e4songen 2025-2026. 2025. Available at: https:\/\/www.adda.se\/upphandling-och-ramavtal\/ramavtal-och-avtalskategorier\/lakemedel\/influensavaccin-sasongen-2025-2026\/ Accessed 2 Mar 2026."},{"key":"1429_CR109","unstructured":"Internetmedicin. Otit (\u00f6roninflammation)\u2014akut. 2024. Available at: https:\/\/www.internetmedicin.se\/oron-nas-och-halssjukdomar\/otit-oroninflammation-akut Accessed 15 Aug 2024."},{"key":"1429_CR110","unstructured":"Internetmedicin. Pneumoni hos vuxna. 2024. Available at: https:\/\/www.internetmedicin.se\/lungsjukdomar\/pneumoni-hos-vuxna Accessed 15 Aug 2024."},{"key":"1429_CR111","unstructured":"Internetmedicin. Pneumoni hos barn. 2025. Available at: https:\/\/www.internetmedicin.se\/barn-och-ungdomsmedicin\/pneumoni-hos-barn Accessed 3 Mar 2026."},{"key":"1429_CR112","unstructured":"Statistiska Centralbyr\u00e5n SCB. Harmonized Index of Consumer Prices, 2015=100. Year 1996\u20132025. 2025. Available at: https:\/\/www.statistikdatabasen.scb.se\/pxweb\/en\/ssd\/START__PR__PR0101__PR0101C\/HIKPAR22015\/ Accessed 3 Mar 2026."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01429-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01429-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01429-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:02:43Z","timestamp":1791864163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01429-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":112,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01429-x","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Petter Brodin is a cofounder of Cytodelics AB and a scientific advisor for Pixelgen Technologies AB, Helaina Inc., Scailyte AG, Oxford Immune Algorithmics Ltd., Sention Health AB, and the Swedish Olympic Committee. He also has ongoing research collaborations with AstraZeneca, Nestl\u00e9, and Pfizer. Fryderyk\u00a0Wilczy\u0144ski, Luca Ricci Pacifici, Peter Gabb, Holly Prudden, and Giorgia Magnatti are\/were employees of Health Economics and Outcomes Research Ltd. Health Economics and Outcomes Research Ltd. received fees from AstraZeneca in relation to this study. Sara Hallberg, \u00c5sa Tormod, Mikko Tuovinen, Amy Zhou, and Klas Bergenheim are employees and may or may not hold stocks in AstraZeneca.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. This study did not require informed consent or institutional\/ethical review board approval because it was based on published data only.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}